anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Stress urinary incontinence (SUI), a common disorder of the pelvic floor, often results in anxiety, poor quality of life, and psychological issues among its sufferers. The relationship between lipid accumulation products (LAP) and stress-related urine incontinence remains unclear. This research aimed to investigate any possible correlation between the risk of SUI and the level of lipid accumulation products.
METHODS: For this cross-sectional research, people with SUI who were 20 years of age or older were recruited using information from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2018. A weighted multivariate logistic regression model was used to evaluate the findings. As a potential biomarker, lipid accumulation product levels were sorted among individuals in ascending order and subjected to a trend test (P for trend). Additionally, a nonlinear analysis was conducted using smooth curve-fitting methods. Lipid accumulation products' effectiveness in predicting SUI was evaluated using receiver operating characteristic (ROC) curves. Finally, a subgroup analysis was performed to confirm that the connection between SUI and lipid accumulation products was consistent across all demographic groups.
RESULTS: A thorough survey performed on 14,945 participants indicated that 23.61% of the respondents had SUI. A noteworthy association was observed between higher lipid accumulation product values and a greater probability of SUI in multivariate logistic regression analysis. Specifically, the stratification of lipid accumulation products into quartiles demonstrated a substantial positive correlation between the upper and lower quartiles, as evidenced by an elevated odds ratio for SUI (OR = 1.92; 95%CI 1.51-2.44; P < 0.0001). The subgroup analysis supported link consistency across all cohorts under investigation. Finally, the ROC curve indicated that lipid accumulation products (AUC = 0.67, 95%CI 0.654-0.690) had a superior predictive effect on the likelihood of SUI.
CONCLUSIONS: Increased lipid accumulation product values are associated with a higher chance of SUI in adult participants. This suggests that lipid accumulation products could be a valuable marker for detecting SUI, offering new perspectives for its evaluation and treatment.
Initial sulcular incisions and flap separation were then carried out with tunnel knives. Dissection was extended at least 8 mm apically to the mucogingival junction and the muscle attachments were removed with curettes so that the flap could be moved in a coronal direction without tension. Interdental papillae were undermined to prepare the bed for connective tissue graft placement. Connective tissue graft was then inserted under the tunnel at the sites of recession and retracted laterally by sutures towards each end of the tunnel. After connective tissue graft positioning, the flap was gently stretched coronally to obtain passive flap closure. The exposed connective tissue was covered by connecting the adjacent flap margins with additional sutures.
Cohort 2 involves screening for eligibility, study treatment and study visits, and follow up. Participants in Cohort 2 will receive study drugs palbociclib and pembrolizumab. Palbociclib is taken orally once per day for 21 days (Day 1-21) of each 28-day cycle. Pembrolizumab will be administered as an intravenous (IV) infusion once every 21 days. Participants may receive study drugs as long as they do not meet the criteria for ending treatment (no intolerable side effects and disease is not progressing), and will be followed for up to 2 years after they stop study treatment. Up to 15 participants will be enrolled in Cohort 2.
PURPOSE: To obtain a compsn. relieving or eliminating pain sensitivity of a tooth very sensitive and algetic to irritants such as cold water and sweetness and feeling a pain. CONSTITUTION: This compsn. for the mouth contains a water-soluble or water- swellable polyelectrolyte or its partial salt contg. a single cation or mixed cations. The polyelectrolyte is, e.g. a methyl vinyl ether-maleic acid (anhydride) copolymer or polyacrylic acid.
Angiogenesis is a complex process that involves the expansion of the pre-existing vascular plexus to enhance oxygen and nutrient delivery and is stimulated by various factors, including hypoxia. Since the process of angiogenesis requires a lot of energy, mitochondria play an important role in regulating and promoting this phenomenon. Besides their roles as an oxidative metabolism base, mitochondria are potential bioenergetics organelles to maintain cellular homeostasis via sensing alteration in oxygen levels. Under hypoxic conditions, mitochondria can regulate angiogenesis through different factors. It has been indicated that unidirectional and bidirectional exchange of mitochondria or their related byproducts between the cells is orchestrated via different intercellular mechanisms such as tunneling nanotubes, extracellular vesicles, and gap junctions to maintain the cell homeostasis. Even though, the transfer of mitochondria is one possible mechanism by which cells can promote and regulate the process of angiogenesis under reperfusion/ischemia injury. Despite the existence of a close relationship between mitochondrial donation and angiogenic response in different cell types, the precise molecular mechanisms associated with this phenomenon remain unclear. Here, we aimed to highlight the possible role of mitochondria concerning angiogenesis, especially the role of mitochondrial transport and the possible relation of this transfer with autophagy, the housekeeping phenomenon of cells, and angiogenesis.
A chimeric protein with an anchor region and anticoagulant activity is described.  Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).  These anticoagulant proteins are prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation. The anchor region can be any entity capable to attaching the protein to the cell lipid bilayer.  These regions can be the transmembrane sequences from membrane proteins such as the HLA class I or CD4 proteins.  Alternatively, the anchor region might be a sequence conferring on the protein the ability to associate extracellularly with a membrane protein without the protein itself being inserted into the cell membrane. The anticoagulant can comprise the sequence of any anticoagulant polypeptide such as heparin, TAPs (tick anticoagulant peptides), antithrombin, hirudins, TFPIs (tissue factor pathway inhibitors) and snake venom factors. The protein further comprises a targeting sequence that prevents the protein from being constitutively expressed at the cell surface.  The targeting sequence is a polypeptide sequence that can target a nascent polypeptide to a secretory granule that does not fuse with the cell's plasma membrane until the cell is suitably stimulated.  For example, Weibel-Palade bodies do not fuse with the plasma membrane until the endothelial cell surface is stimulated by a secretagogue, such as thrombin or fibrin. Figure 1 shows maps of hirudin-CD4 chimeric proteins and constructs.  (A) HLA-hirudin-CD4 constructs with glycine linkers. (B) HLA-hirudin-CD4 construct with human P-selectin C-terminal, with the specific targeting sequence underlined.
Tumor endothelial marker-1 also referred to as TEM-1 is expressed in the supportive tissue, as well as, on the cells within the tumor. TEM-1, which is a cell surface glycoprotein, and is expressed in the stromal compartment (cells) of nearly all human tumors. In preclinical studies, it has been shown that TEM-1 plays a key role in tumor growth and the vascularization of tumors. There is evidence suggesting an association between the level of TEM-1, 7, 7R, 8 in relation to lymph node involvement and disease progression. MORAb-004 is a humanized immunoglobulin G (IgG1/κ) antibody directed against endosialin/TEM-1. Nonclinical pharmacological studies showed that MORAb-004 has the ability to block specific TEM-1 receptor-ligand interactions. Immunohistochemistry studies of human tumor biopsy samples demonstrate TEM-1 expression and MORAb-004 binding to tumor stromal cells, in particular mural cell compartment of neovessels and cancer-associated fibroblasts. All of which suggests a potential effective treatment. Researchers hypothesize that an antibody therapy that binds to TEM-1 may be efficacious in the treatment of metastatic, colorectal cancer. This clinical study is a proof of concept study to see if an anti-TEM-1 agent is safe and effective in the treatment of metastatic, colorectal cancer.
The invention relates to the medicine and may be used for treating osteoporosis in the rheumatologic patients. The treatment course provides for drinking daily the mineral water with calcium content at least 200 mg/L followed by hydrolaser shower equipped with helium-neon laser at 632.8 nm and the output of 25-30 mW. The following regions are treated: epigastral area, the areas of the liver, the kidneys, the affected joints, and/or the backbone. Each session, the duration of the procedure and the temperature of the water increase relative to the previous ones. The hydrolaser shower is followed by the ultrasound reflex therapy at 22 kHz. The acupuncture points specific of the liver, the kidneys, the stomach, the intestine, the joints, and/or the backbone are involved. The areas of the lymphatic nodes is exposed to the ultrasound at 24 kHz. The overall duration of the treatment is 24 days.
BACKGROUND AND OBJECTIVES: Atrial fibrillation (AF) is a widespread cardiac arrhythmia that significantly impacts heart function. AF disrupts atrial mechanical contraction, leading to irregular, uncoordinated, and slow blood flow inside the atria which favors the formation of clots, primarily within the left atrium (LA). A standardized region-based analysis of the LA is missing, and there is not even any consensus about how to define the LA regions. In this study we propose an automatic approach for regionalizing the LA into segments to provide a comprehensive 3D region-based LA contraction assessment. LA global and regional contraction were quantified in control subjects and in AF patients to describe mechanical abnormalities associated with AF.
METHODS: The proposed automatic approach for LA regionalization was tested in thirteen control subjects and seventeen AF patients. After dividing LA into standard regions, we evaluated the global and regional mechanical function by measuring LA contraction parameters, such as regional volume, global and regional strains, regional wall motion and regional shortening fraction.
RESULTS: LA regionalization was successful in all study subjects. In the AF group compared with control subjects, results showed: a global impairment of LA contraction which appeared more pronounced along radial and circumferential direction; a regional impairment of radial strain which was more pronounced in septal, inferior, and lateral regions suggesting a greater reduction in mechanical efficiency in these regions in comparison to the posterior and anterior ones.
CONCLUSION: An automatic approach for LA regionalization was proposed. The regionalization method was proved to be robust with several LA anatomical variations and able to characterize contraction changes associated with AF.
The immunogenicity of anti-tumor necrosis factor alpha (anti-TNF) therapy in inflammatory bowel disease (IBD) is an important cause of loss of response to therapy that may lead to escalation of dose or discontinuation of therapy. Antibodies may develop to infliximab (ATI) or to adalimumab (ATA) and cause this loss of response, also known as a secondary loss of response. In an attempt to overcome these antibodies, dose escalation can be accomplished either by increasing the dose or shortening the interval between doses. The ability of dose escalation to overcome loss of response due to the presence of ATI or ATA remains controversial. Escalation of dose increases the cost of therapy substantially. If the decision is made to discontinue therapy after a secondary loss of response, a clinician may choose to switch to an alternate anti-TNF therapy of which there are currently only four. Loss of response to one agent predicts a lesser response to other anti-TNF agents and with a limited number of therapeutic options the goal should be to optimize therapy rather than to discontinue therapy.

An alternative approach is the addition of immunomodulator (IM) therapy to counteract the antibody response and regain efficacy of the biologic medication. Three such IMs known to be effective in the treatment of IBD are azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX). The SONIC trial showed that patients on infliximab and azathioprine only developed antibodies at 4% of the time as opposed to those on infliximab monotherapy who formed ATI at 13%. The same principal was shown during the COMMIT trial in which patients on infliximab alone had ATI at a rate of 20% versus 4% on methotrexate plus infliximab. Ben-Horin et al. reported five patients treated initially with infliximab monotherapy whom had secondary loss of response based on clinical symptoms. These patients had ATI and all had undetectable troughs of infliximab. In all five patients ATI became undetectable, an adequate trough level was restored and the patients regained clinical response with the addition of an immunomodulator. Combination therapy with azathioprine and infliximab has led to a higher percentage of patients in steroid free remission than either drug alone. Our goal is to treat patients' who have lost response to adalimumab or infliximab with an immunomodulator with the goal of eliminating the circulating antibodies to the anti-TNF and restoring efficacy.
The Intervention Group will receive 9 physical rehabilitation sessions using the MAK device. Each session will consist of approximately 90 minutes.
The experimental drug (Resusix) will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
Participants will receive IV administration of saline only placebo prior to a PET examination. This is followed by a single SC dose of AZD3427 on Day 1 (V2).
This group will facilitate collection of paired clinical and molecular data done as part of the standard of care or routine clinical care across a variety of institutions. The goal of Group 1 is to capture a broad range of participants to better understand longitudinal outcomes across institutions and standards of care.
The present invention relates to a pharmaceutical composition, a functional health food, and a feed composition, for innate immune-boosting and antiviral purposes, containing a Benincasae Exocarpium extract as an active ingredient. The present invention further relates to a method for boosting innate immunity and increasing antiviral activities in animals, including a step of injecting the Benincasae Exocarpium extract into animals requiring enhancement of innate immunity, not including human. According to the present invention, the Benincasae Exocarpium composition for innate immune-boosting and antiviral purposes shows effectiveness in boosting innate immunity and antiviral activities, and thus the composition can be used for preventing and treating infectious disease caused by bacteria and virus. In addition, the Benincasae Exocarpium composition can be widely used as drugs or functional health foods for boosting and regulating immunity in a patient with weakened or suppressed immunity, and also as feeds for innate immune-boosting and antiviral purposes for strengthening an anti-disease immune system in animals. Furthermore, the composition for innate immune-boosting and antiviral purposes, according to the present invention, barely causes toxicity or side effects. Thus, the composition can be used with ease even for a long period of time in order to prevent disease.
The DTx group was asked to download and install a smartphone application (WonderLab Harbor) that incorporated Internet-based Cognitive Behavioral Therapy (ICBT), Approach Bias Modification (ApBM), cognitive function training, and Contingency Management (CM). During the 8-week treatment program, the participants in the DTx group were instructed to complete ICBT, cognitive trainings, and ApBM trainings. Reward points (which can be redeemed for cellphone plan credit) were rewarded following completing each task as part of the positive reinforcement following CM principles.
The invention discloses a traditional Chinese medicine preparation for treating coronary heart diseases. The preparation comprises the following raw materials in parts by weight: 20-30 parts of fragrant solomonseal rhizome, 10-15 parts of asiatic cornelian cherry fruit, 10-15 parts of garden burnet root, 5-8 parts of fried spina date seeds, 5-8 parts of dandelion, 20-30 parts of radix adenophorae, 30-40 parts of sanqi, 5-15 parts of China dodder, 15-30 parts of dangshen, 10-15 parts of prepared rhizome of rehmannia, 10-20 parts of honeysuckle, 10-20 parts of white paeony root, 5-15 parts of cogon grass rhizome, 20-35 parts of draconis resin, 15-25 parts of manchurian wildginger and 5-20 parts of creeping euphorbia. During treatment, the preparation is orally taken. Ten days is a course of treatment. Generally, the preparation takes effect after one course of treatment and the patients become better obviously or recover after two-three courses of treatment. The traditional Chinese medicine preparation has the advantages that 1. the traditional Chinese medicine preparation is a pure natural traditional Chinese medicine and has low toxic and side effects and unique treatment effects; and 2. the traditional Chinese medicine preparation takes effect quickly and has definite curative effects, and clinical application of more than 400 patients verifies that the effective rate of the traditional Chinese medicine preparation can reach 97.9%.
Acute pancreatitis (AP) is a common digestive emergency, needs early prediction and recognition. The study examined the clinical value of long non-coding RNA SNHG1 in AP, and explored its related mechanism for AP. A total of 288 AP cases and 150 healthy persons were recruited, the AP patients were grouped based on AP severity. AR42J cells were treated with 100nM caerulein to stimulate AP in vitro. qRT-PCR was performed for mRNA detection. Receiver operating characteristic (ROC) curve was drawn for diagnostic significance evaluation. The relationship of SNHG1 and miR-140-3p was verified via luciferase reporter and RNA immunoprecipitation (RIP) assay. AP cases had high expression of SNHG1, and it can differentiate AP cases from healthy people with the area under the curve (AUC) of 0.899. Severe AP cases had high values of SNHG1, which was independently related to AP severity. SNHG1 knockdown relieved caerulein-induced AR42J cell apoptosis and inflammatory response. miR-140-3p interacted with SNHG1, and reversed the role of SNHG1 in caerulein-induced AR42J cell injury. RAB21 was a candidate target of miR-140-3p, and was at high expression in AP cell models. SNHG1 may be a promising biomarker for the detection of AP, and serves as a potential biological marker for further risk stratification in the management of AP. SNHG1 knockdown can relieve inflammatory responses and pancreatic cell apoptosis by absorbing miR-140-3p.
INTRODUCTION AND HYPOTHESIS: Sacrospinous ligament fixation (SSLF) is a popular surgical technique for treating apical prolapse. The use of suture-capturing devices (SCD), or the more recently introduced anchor-based device (ABD), is useful for a posterior approach but essential for an anterior one. The aim of our study was to assess the safety of the ABD, which was recently introduced to our unit, compared to the traditionally used SCD.
METHODS: This was a pilot case-control study of 40 patients who had a SSLF, 20 of these represented all the patients who had the procedure with the aid of the ABD and 20 patients who had the procedure using the SCD over approximately the same duration. The main safety endpoints of this pilot study were patient reported postoperative pain scores and perioperative complications rate.
RESULTS: The population characteristics were similar. The mean postoperative pain scores differed significantly only on postoperative day 1 in favor of the suture capturing device (3.40 [2.60] vs 1.60 [1.64], p = 0.013). The mean highest pain score was similar in both groups. Peri-operative complications rates were low and comparable between both groups. According to POPQ at 6 weeks follow-up the median Ba point was higher in the ABD group and this difference was significant (-3.00 [-3.00; -2.25] vs. -2.00 [-3.00; -1.50]; p = 0.03).
CONCLUSION: The anchor-based device for sacrospinal ligament fixation seems to have comparable safety profile to the traditionally used suture capturing devices.
New antihypercholesterolaemic compsns, comprise a deconjugated bile acid or one of its salts and total dried pancreas in a wt. ratio 1:2 to 1:3. Bile acids include cholic, deoxycholic and chenodeoxycholic acids. Pref. is sodium deoxycholate. Pref. compsn. contain sodium deoxycholate and freeze-dried whole pancreas in a ratio of 1:2. The pancreas contains at least 40000 i.u./g of lipase. Typically, a tablet contg. 100 mg of sodium deoxycholate and 200 mg of freeze-dried whole pancreas, given 4 times daily for 6-8 weeks, reduced the blood cholesterol levels in 7 patients by 9,10,10,14,17,27 and 35%.